354 related articles for article (PubMed ID: 25660252)
21. Treatment for older men with fractures.
Shepherd AJ; Cass AR; Ray LA; Tan A; Wilkinson GS
Osteoporos Int; 2012 Mar; 23(3):1041-51. PubMed ID: 21811867
[TBL] [Abstract][Full Text] [Related]
22. Preventing future fractures: effectiveness of an orthogeriatric fracture liaison service compared to an outpatient fracture liaison service and the standard management in patients with hip fracture.
Naranjo A; Fernández-Conde S; Ojeda S; Torres-Hernández L; Hernández-Carballo C; Bernardos I; Rodríguez S; Laynez P
Arch Osteoporos; 2017 Dec; 12(1):112. PubMed ID: 29230540
[TBL] [Abstract][Full Text] [Related]
23. Geographic variation in secondary fracture prevention after a hip fracture during 1999-2013: a UK study.
Shah A; Prieto-Alhambra D; Hawley S; Delmestri A; Lippett J; Cooper C; Judge A; Javaid MK;
Osteoporos Int; 2017 Jan; 28(1):169-178. PubMed ID: 27812809
[TBL] [Abstract][Full Text] [Related]
24. Primary and secondary non-adherence to osteoporotic medications after hip fracture in Spain. The PREV2FO population-based retrospective cohort study.
García-Sempere A; Hurtado I; Sanfélix-Genovés J; Rodríguez-Bernal CL; Gil Orozco R; Peiró S; Sanfélix-Gimeno G
Sci Rep; 2017 Sep; 7(1):11784. PubMed ID: 28924156
[TBL] [Abstract][Full Text] [Related]
25. Undertreatment of osteoporosis following hip fracture: a retrospective, observational study in Singapore.
Chau YT; Nashi N; Law LS; Goh RKH; Choo SX; Seetharaman SK
Arch Osteoporos; 2020 Sep; 15(1):141. PubMed ID: 32918196
[TBL] [Abstract][Full Text] [Related]
26. Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009.
Balasubramanian A; Tosi LL; Lane JM; Dirschl DR; Ho PR; O'Malley CD
J Bone Joint Surg Am; 2014 Apr; 96(7):e52. PubMed ID: 24695929
[TBL] [Abstract][Full Text] [Related]
27. Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA.
Wilk A; Sajjan S; Modi A; Fan CP; Mavros P
Osteoporos Int; 2014 Dec; 25(12):2777-86. PubMed ID: 25112720
[TBL] [Abstract][Full Text] [Related]
28. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
[TBL] [Abstract][Full Text] [Related]
29. Two-year adherence to treatment and associated factors in a fracture liaison service in Spain.
Naranjo A; Ojeda-Bruno S; Bilbao-Cantarero A; Quevedo-Abeledo JC; Diaz-González BV; Rodríguez-Lozano C
Osteoporos Int; 2015 Nov; 26(11):2579-85. PubMed ID: 26048675
[TBL] [Abstract][Full Text] [Related]
30. Patients' first-year adherence to different anti-osteoporotic therapy after hip fractures.
Kim SJ; Cho YJ; Lee DW
Injury; 2021 Jun; 52(6):1506-1510. PubMed ID: 33223260
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients-a nationwide register-based open cohort study.
Bondo L; Eiken P; Abrahamsen B
Osteoporos Int; 2013 Jan; 24(1):245-52. PubMed ID: 22638712
[TBL] [Abstract][Full Text] [Related]
32. Low rate of densitometric diagnosis and treatment in patients with severe osteoporosis in Colombia.
Fernández-Ávila DG; Rincón-Riaño DN; Pinzón DF; Gutiérrez Dávila JM
Arch Osteoporos; 2019 Sep; 14(1):95. PubMed ID: 31486920
[TBL] [Abstract][Full Text] [Related]
33. Examining the treatment gap and risk of subsequent fractures among females with a fragility fracture in the US Medicare population.
Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
Osteoporos Int; 2017 Aug; 28(8):2485-2494. PubMed ID: 28536737
[TBL] [Abstract][Full Text] [Related]
34. Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study.
Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
Osteoporos Int; 2016 Jan; 27(1):387-96. PubMed ID: 26576544
[TBL] [Abstract][Full Text] [Related]
35. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.
Siris ES; Harris ST; Rosen CJ; Barr CE; Arvesen JN; Abbott TA; Silverman S
Mayo Clin Proc; 2006 Aug; 81(8):1013-22. PubMed ID: 16901023
[TBL] [Abstract][Full Text] [Related]
36. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan.
Soong YK; Tsai KS; Huang HY; Yang RS; Chen JF; Wu PC; Huang KE
Osteoporos Int; 2013 Feb; 24(2):511-21. PubMed ID: 22588182
[TBL] [Abstract][Full Text] [Related]
37. Hip fracture trends in the United States, 2002 to 2015.
Lewiecki EM; Wright NC; Curtis JR; Siris E; Gagel RF; Saag KG; Singer AJ; Steven PM; Adler RA
Osteoporos Int; 2018 Mar; 29(3):717-722. PubMed ID: 29282482
[TBL] [Abstract][Full Text] [Related]
38. Trends in hospital care for hip fractures.
Gehlbach SH; Avrunin JS; Puleo E
Osteoporos Int; 2007 May; 18(5):585-91. PubMed ID: 17146592
[TBL] [Abstract][Full Text] [Related]
39. Screening and treatment of osteoporosis after hip fracture: comparison of sex and race.
Antonelli M; Einstadter D; Magrey M
J Clin Densitom; 2014; 17(4):479-83. PubMed ID: 24657109
[TBL] [Abstract][Full Text] [Related]
40. Subjects with osteoporosis to remain at high risk for fracture despite benefit of prior bisphosphonate treatment-a Danish case-control study.
Hansen L; Petersen KD; Eriksen SA; Gerstoft F; Vestergaard P
Osteoporos Int; 2017 Jan; 28(1):321-328. PubMed ID: 27475930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
